Liver transplantation and autoimmune hepatitis

Intractable and Rare Diseases Research

Volumn 4, Issue 1, 2015, Pages 33-38

  Tanaka, Tomohiro ^a   Sugawara, Yasuhiko ^b   Kokudo, Norihiro ^b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anti nuclear antibody (ANA); Autoimmune hepatitis (AIH); De novo AIH; Liver transplantation; Rejection

Indexed keywords

ACUTE LIVER FAILURE; AUTOIMMUNE HEPATITIS; BONE DENSITY; CHRONIC LIVER FAILURE; CLINICAL FEATURE; DE NOVO AUTOIMMUNE HEPATITIS; END STAGE LIVER DISEASE; GRAFT SURVIVAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RECURRENT AUTOIMMUNE HEPATITIS; REVIEW; RISK FACTOR; TREATMENT INDICATION;

EID: 84942195119     PISSN: 21863644     EISSN: 2186361X     Source Type: Journal    
DOI: 10.5582/irdr.2014.01034     Document Type: Review

References (70)

1. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006; 43:S132-144.
2. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006; 354:54-66.
3. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996; 110:848-857.
4. Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. World J Gastroenterol. 2008; 14:3388-3395.
5. Reich DJ, Fiel, Guarrera JV, Emre S, Guy SR, Schwartz ME, Miller CM, Sheiner PA. Liver transplantation for autoimmune hepatitis. Hepatology. 2000; 32:693-700.
6. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992; 15:215-221.
7. Czaja AJ, Freese DK; American Association for the Study of Liver D. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002; 36:479-497.
8. El-Masry M, Puig CA, Saab S. Recurrence of non-viral liver disease after orthotopic liver transplantation. Liver Int. 2011; 31:291-302.
9. Guido M, Burra P. De novo autoimmune hepatitis after liver transplantation. Semin Liver Dis. 2011; 31:71-81.
10. Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: What have we learned so far? Transpl Int. 2009; 22:144-152.
11. Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007; 13:996-1003.
12. Verma S, Maheshwari A, Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: Clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology. 2009; 49:1396-1397.
13. Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, Verucchi G, Cassani F, Chiodo F, Bianchi FB. Type 1 autoimmune hepatitis: Patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM. 2004; 97:407-12.
14. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31:929-938.
15. Tamura S, Sugawara Y, Kaneko J, Togashi J, Matsui Y, Yamashiki N, Kokudo N, Makuuchi M. Recurrence of cholestatic liver disease after living donor liver transplantation. World J Gastroenterol. 2008; 14:5105- 5109.
16. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant. 2005; 5:307-313.
17. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: Asystematic review of 118 studies. J Hepatol. 2006; 44:217-231.
18. Freeman RB Jr, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, Klintmalm G, Blazek J, Hunter R, Punch J. Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl. 2006; 12:S128-136.
19. Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I, Morillas RM, Coll S, Solà R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006; 4:1385-1394.
20. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM, Lake JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: A report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation. 1998; 66:956-962.
21. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, Rodés J. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999; 30:890-895.
22. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48:169-176.
23. Potts JR, Verma S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. World J Gastroenterol. 2011; 17:2070-2075.
24. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: A histological feature associated with acute clinical presentation. J Clin Pathol. 2006; 59:246-249.
25. I l y a s J A , O ' M a h o n y C A , Vi e r l i n g J M . L i v e r transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol. 2011; 25:765-782.
26. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987-1998: Updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl. 1998:17-37.
27. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry. Liver Transpl. 2003; 9:1231-1243.
28. Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, Hasegawa K, Sakamoto Y, Koike K, Kokudo N. Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Hepatol Res. 2012; 42:1016- 1023.
29. Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS Liver Transplant Registry. Clin Transpl. 2004:315-329.
30. Neuberger J. Transplantation for autoimmune hepatitis. Semin Liver Dis. 2002; 22:379-386.
31. Haga H, Miyagawa-Hayashino A, Taira K, Morioka D, Egawa H, Takada Y, Manabe T, Uemoto S. Histological recurrence of autoimmune liver diseases after livingdonor liver transplantation. Hepatol Res. 2007; 37(Suppl) 3:S463-469.
32. Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014; 60:210-223.
33. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation. 1984; 37:363-365.
34. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002; 8:519-26.
35. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli- Vergani G, Vergani D, Vierling JM; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51:2193-2213.
36. Banff Working G, Demetris AJ, Adeyi O, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology. 2006; 44:489-501.
37. Prados E, Cuervas-Mons V, de la Mata M, Fraga E, Rimola A, Prieto M, Clemente G, Vicente E, Casanovas T, Fabrega E. Outcome of autoimmune hepatitis after liver transplantation. Transplantation. 1998; 66:1645-1650.
38. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999; 68:253-256.
39. Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P, Farahmand H, Gigou M, Féray C, Reynès M, Bismuth H. Long-term follow-up after liver transplantation for autoimmune hepatitis: Evidence of recurrence of primary disease. J Hepatol. 1999; 30:131-141.
40. González-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, Rosen CB, Wiesner RH. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001; 7:302-310.
41. Yusoff IF, House AK, De Boer WB, Ferguson J, Garas G, Heath D, Mitchell A, Jeffrey GP. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol. 2002; 17:203-207.
42. Heffron TG1, Smallwood GA, Oakley B, Pillen T, Welch D, Martinez E, Romero R, Stieber AC. Autoimmune hepatitis following liver transplantation: Relationship to recurrent disease and steroid weaning. Transplant Proc. 2002; 34:3311-3312.
43. Renz JF, Ascher NL. Liver transplantation for nonviral, nonmalignant diseases: Problem of recurrence. World J Surg. 2002; 26:247-256.
44. Duclos-Vallée JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, Karam V, Hurtova M, Feray C, Reynes M, Bismuth H, Samuel D. A 10 year follow up study of patients transplanted for autoimmune hepatitis: Histological recurrence precedes clinical and biochemical recurrence. Gut. 2003; 52:893-897.
45. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J, Nashan B, Manns MP, Strassburg CP. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004; 18:62- 69.
46. Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009; 15:1254-1261.
47. Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl. 2013; 19:1065-1077.
48. Wright HL, Bou-Abboud CF, Hassanein T, Block GD, Demetris AJ, Starzl TE, Van Thiel DH. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation. 1992; 53:136-139.
49. Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM, Wei YL, Rakela J, Schafer DF, Roberts JP, Everhart JE, Wiesner RH. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology. 2008; 48:878-888.
50. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: A systematic review. Liver Transpl. 2006; 12:1813-24.
51. Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: Is it corticosteroid-dependent after liver transplantation? Liver Transpl Surg. 1999; 5:460-463.
52. Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology. 2002; 36:271-276.
53. Hurtova M, Duclos-Vallée JC, Johanet C, Emile JF, Roque-Afonso AM, Feray C, Bismuth H, Samuel D. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl. 2001; 7:556-558.
54. Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant. 2005; 5:1085-1089.
55. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, Heaton ND, Vergani D, Mieli-Vergani G. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998; 351:409-413.
56. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: A rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation. 2001; 71:664-668.
57. Hernandez HM1, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr. 2001; 32:131-136.
58. Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, Tanaka K, Manabe T. Outcome and risk factors of de novo autoimmune hepatitis in livingdonor liver transplantation. Transplantation. 2004; 78:128- 135.
59. Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, Ament ME, Busuttil RW. Rejection and steroid dependence: Unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant. 2007; 7:955-963.
60. Eguchi S, Takatsuki M, Hidaka M, Tajima Y, Zen Y, Nakanuma Y, Kanematsu T. De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease. J Gastroenterol Hepatol. 2008; 23:e165-169.
61. Cho JM, Kim KM, Oh SH, Lee YJ, Rhee KW, Yu E. De novo autoimmune hepatitis in Korean children after liver transplantation: A single institution's experience. Transplant Proc. 2011; 43:2394-2396.
62. Richter A, Grabhorn E, Helmke K, Manns MP, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant. 2007; 21:427-432.
63. Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci. 2012; 57:2248-2266.
64. Salcedo M, Vaquero J, Bañares R, Rodríguez-Mahou M, Alvarez E, Vicario JL, Hernández-Albújar A, Tíscar JL, Rincón D, Alonso S, De Diego A, Clemente G. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002; 35:349-356.
65. Aguilera I, Wichmann I, Sousa JM, Bernardos A, Franco E, García-Lozano JR, Núñez-Roldán A. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol. 2001; 126:535-39.
66. Aguilera I, Sousa JM, Praena JM, Gómez-Bravo MA, Núñez-Roldan A. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. Clin Transplant. 2011; 25:207-212.
67. Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: Possible de novo autoimmune hepatitis? Gut. 2007; 56:237-242.
68. Ueda Y, Yoshizawa A, Ogura Y, Miyagawa-Hayashino A, Haga H, Chiba T, Uemoto S. Plasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2014; 44:E279-283.
69. Ikegami T, Yoshizumi T, Shirabe K, Maehara Y. Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation. J Hepatol. 2014; 60:894-896.
70. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, Heaton ND, O'Grady JG. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology. 2001; 34:464- 470.